Two distinct peptides in this set: CJC-1295 (No DAC), also called Modified GRF(1-29), and Ipamorelin (NNC 26-0161). An identity fact, not a product claim.
Form Labs research guidePlain-English research guideModified GRF (1-29) / NNC 26-0161
CJC-1295 No DAC and Ipamorelin research guide
Everything worth knowing, without the jargon.
Jette et al. (Endocrinology, 2005) reported findings for CJC-1295 with DAC, separate from the no-DAC material listed here. Raun et al. (European Journal of Endocrinology, 1998) reported Ipamorelin measurements in animals. Neither compound is an approved medicine in this guide's record.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
REV 2026-10 ยท 1 Oct 20263 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
The year Ipamorelin was first described (Raun and colleagues). A research-history fact, not a product claim.
Raun et al., European Journal of Endocrinology, 1998Ipamorelin is a five-amino-acid (pentapeptide) agonist at the ghrelin receptor (GHS-R1a). An identity fact, not a product claim.
Raun et al., 1998; Howard et al., Science, 1996Why it matters
Why are CJC-1295 No DAC and Ipamorelin studied?
Jette et al. (Endocrinology, 2005) reported longer persistence for albumin-binding CJC-1295 with DAC; that finding does not describe CJC-1295 (No DAC). Raun et al. (European Journal of Endocrinology, 1998) reported Ipamorelin findings in animal experiments, including growth-hormone and stress-hormone measurements. The papers concern separate compounds and models, rather than a clinical result for their combination.
Two peptides, two parts of the GH axis.
The CJC-1295 (No DAC) and Ipamorelin guide separates the DAC-modified compound studied by Jette et al. (Endocrinology, 2005) from the animal Ipamorelin experiments reported by Raun et al. (European Journal of Endocrinology, 1998). Neither paper establishes a clinical outcome for the listed combination.
Jette et al. (Endocrinology, 2005) reported albumin binding and longer persistence for CJC-1295 with DAC; the results do not describe the no-DAC material. Raun et al. (European Journal of Endocrinology, 1998) reported growth-hormone and stress-hormone measurements in animal experiments with Ipamorelin. The papers do not establish a combined clinical outcome.
The source guide keeps study context separate from Form Labs product claims.
Study observations
What laboratory observations have CJC-1295 No DAC and Ipamorelin studies reported?
Jette et al. (Endocrinology, 2005) reported longer persistence for albumin-binding CJC-1295 with DAC; that finding does not describe CJC-1295 (No DAC). Raun et al. (European Journal of Endocrinology, 1998) reported Ipamorelin findings in animal experiments, including growth-hormone and stress-hormone measurements. The papers concern separate compounds and models, rather than a clinical result for their combination.
Separate CJC-1295 and Ipamorelin records Findings stay tied to the cited study and its model.
DAC distinction
Jette et al. (Endocrinology, 2005) reported albumin binding and longer persistence for the DAC-modified compound; this is background rather than direct no-DAC evidence.
Receptor identification
Howard et al. (Science, 1996) identified a growth-hormone secretagogue receptor in pituitary and hypothalamic tissue; this is a receptor study.
Ipamorelin animal observations
Raun et al. (European Journal of Endocrinology, 1998) reported growth-hormone release without a significant ACTH or cortisol rise at the studied levels in animals; the response was reduced, not abolished.
Pharmacology at a glance
- Research code
- Modified GRF (1-29) / NNC 26-0161
- Class
- two distinct peptides - a short-acting GHRH analog (CJC-1295 No DAC / Modified GRF(1-29)) and a ghrelin-receptor agonist (Ipamorelin / NNC 26-0161). Class wording here means the research category named by the source guide.
- Molecule
- Two-material research record. CJC-1295 (No DAC), also called Modified GRF(1-29), is a short-acting lab-made analog of growth-hormone-releasing hormone. Ipamorelin, also called NNC 26-0161, is a five-amino-acid ghrelin-receptor (GHS-R1a) agonist listed separately. Neither supplies growth hormone directly.
- Reported half-life
- Not listed in the source guide for this consumer entry; half-life means the time for a measured amount to fall by half.
- Originator
- Not listed in the source guide; Form Labs did not run the cited studies.
- Approval status
- Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine - neither is on the Australian Register of Therapeutic Goods, and the TGA has not evaluated either for safety, quality or effectiveness. Ipamorelin's clinical development was discontinued. Both are on the World Anti-Doping Agency (WADA) Prohibited List. Supplied strictly as laboratory research materials, not for human use.
What it has been studied for
What have CJC-1295 No DAC and Ipamorelin been studied for?
CJC-1295 (No DAC) and Ipamorelin research covers three study areas: the long-acting 'with DAC' form of CJC-1295 and its albumin binding, the ghrelin receptor GHS-R1a that Ipamorelin acts at, and the first description of Ipamorelin as a selective growth-hormone secretagogue. The first area is background, not direct no-DAC evidence. All three are pathway or identity records.
Study areas from the published literature.
CJC-1295 'with DAC' background
Study topic: the long-acting 'with DAC' form of CJC-1295 and its albumin-binding, included as context for the no-DAC material on this page - not direct no-DAC evidence.
Jette et al., Endocrinology, 2005Ipamorelin receptor context
Study topic: the ghrelin receptor (GHS-R1a) that Ipamorelin acts at; receptor means a cell-signal receiver.
Howard et al., Science, 1996Ipamorelin identity
Study topic: the first description of Ipamorelin as a selective growth-hormone secretagogue; an identity record, not a use instruction.
Raun et al., European Journal of Endocrinology, 1998The studies
What did the CJC-1295 No DAC and Ipamorelin studies find?
The three studies behind the CJC-1295 (No DAC) and Ipamorelin guide are laboratory and animal work, not human trials. Jette et al. (Endocrinology, 2005) described the long-acting 'with DAC' form of CJC-1295. Howard et al. (Science, 1996) identified the ghrelin receptor GHS-R1a that Ipamorelin acts at. Raun et al. (European Journal of Endocrinology, 1998) first described Ipamorelin as a selective growth-hormone secretagogue.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
The paper describing how the long-acting 'with DAC' form of CJC-1295 was built to survive in the bloodstream. Background for this page, not evidence about the short-acting no-DAC material listed here.
- Studied in
- Laboratory binding experiments and animal studies.
- Design
- The researchers attached a chemical group - the DAC - to a GHRH analog so it would latch onto albumin, a carrier protein circulating in blood, then compared how long the modified peptide persisted against the unmodified version.
- Measured
- How long the peptide stayed detectable in the bloodstream, and whether growth-hormone release followed.
The DAC-modified version lasted dramatically longer than the plain GHRH analog, because riding on albumin let it escape the rapid breakdown that normally clears these peptides within minutes (Jette et al., Endocrinology, 2005). This is precisely why the distinction matters here: the material listed on this page is the short-acting no-DAC form, so this paper's durability results do not describe it (Jette et al., Endocrinology, 2005).
DOI 10.1210/en.2004-1286The paper that found the receptor Ipamorelin acts on - before anyone knew what the body's own signal for it was.
- Studied in
- Pituitary tissue, with the receptor then expressed in cultured cells.
- Design
- The researchers worked backwards from compounds already known to trigger growth-hormone release, hunting for the cell-surface receptor those compounds bound to, then cloned it.
- Measured
- Whether the cloned receptor responded when those compounds were applied to cells carrying it.
They identified a distinct receptor, later named GHS-R1a, separate from the already-known GHRH receptor (Howard et al., Science, 1996). At the time it was an orphan receptor - a lock with no known key, since ghrelin, the body's own molecule that fits it, was not discovered until 1999 (Howard et al., Science, 1996). Ipamorelin acts at this receptor, which is what makes it a fundamentally different kind of compound from CJC-1295 (Howard et al., Science, 1996).
DOI 10.1126/science.273.5277.974The paper that first described Ipamorelin, and made the case that it was unusually selective.
- Studied in
- Cultured pituitary cells plus animal studies.
- Design
- Ipamorelin was compared against other growth-hormone secretagogues, looking not only at whether growth hormone was released but at which other hormones moved at the same time.
- Measured
- Growth-hormone release, alongside ACTH and cortisol - two stress-axis hormones that the earlier secretagogues tended to disturb.
At the amounts that released growth hormone, Ipamorelin did not produce a significant rise in ACTH or cortisol - the two stress-axis hormones the earlier secretagogues tended to move (Raun et al., European Journal of Endocrinology, 1998). That is a reduced response in this study, not an abolished one (Raun et al., European Journal of Endocrinology, 1998). That selectivity is why it kept appearing in later research (Raun et al., European Journal of Endocrinology, 1998). Its clinical development was nonetheless discontinued, and it is not an approved medicine (Raun et al., European Journal of Endocrinology, 1998).
DOI 10.1530/eje.0.1390552Evidence and limitations
What does the CJC-1295 No DAC and Ipamorelin research mean, and what does it not?
The CJC-1295 (No DAC) and Ipamorelin guide is a literature map, not a product claim. The cited papers give identity, pathway and analytical context, and the durability results come from the 'with DAC' form of CJC-1295, not the no-DAC material. Where the source guide does not list participant counts or study details, this page does not invent them.
The source guide is a literature map, not a product claim
The cited papers are used for identity, pathway, marker, model, or analytical context. They do not become Form Labs results or promises.
Study details are limited to the source record
Where the source guide does not list participant counts, model details, study amounts, or study-stage labels, this page does not invent them.
Label and available report
Storage and batch decisions should follow the product label and any verified matching COA. Source storage note: Use the product label and any available report..
Lab handling
How are CJC-1295 No DAC and Ipamorelin handled as reference material?
CJC-1295 (No DAC) and Ipamorelin are laboratory reference material, not for human consumption or veterinary use. Storage and lot checks follow the product label and any verified matching certificate of analysis (COA). This guide's catalogue record notes storage at 2-8 C and protection from light. Historical sample reports do not verify current lot identity, purity or release status.
Research-use boundary
Follow the product label and laboratory procedures for storage. Historical sample reports do not establish current lot identity, purity or release status.
Educational boundary
This guide summarises third-party literature; Form Labs did not run the cited studies.
Research-use boundary
For laboratory research use only. 21+ only. Not for human consumption or veterinary use.
Glossary
Plain-English definitions.
- GHRH
- Growth-hormone-releasing hormone; the natural hormone a GHRH analog is built to resemble.
- GHRH analog
- A lab-made molecule built to resemble growth-hormone-releasing hormone. CJC-1295 (No DAC) / Modified GRF(1-29) is one example.
- Modified GRF(1-29)
- The research name for the no-DAC form of CJC-1295 - a short-acting lab-made GHRH analog covering amino-acid positions 1 through 29.
- DAC
- Drug Affinity Complex - a binding tag on the 'with DAC' form of CJC-1295 that attaches to albumin in the blood and extends its half-life. The no-DAC form on this page does not have it.
- Growth-hormone secretagogue
- A compound studied for prompting the body's own release of growth hormone. Ipamorelin is one example. Such compounds do not supply growth hormone themselves.
- GHS-R1a
- The ghrelin receptor - a cell-signal receiver - at which Ipamorelin acts.
- Ghrelin
- A hormone that acts at the GHS-R1a receptor; named here only to identify the research pathway Ipamorelin acts on.
- Glucose measurements
- Insulin-like growth factor 1; a marker linked to GH in endocrine research.
- Pentapeptide
- A peptide made from five amino acids. Ipamorelin is a pentapeptide.
- COA
- Certificate of analysis; the batch paperwork that controls identity, purity, appearance, and release checks.
- Research use only
- A lab-only boundary. It means not for human consumption, veterinary use, medical use, or cosmetic use.
- Literature context
- A plain summary of what cited papers discuss, not a product result.
FAQ
What are the most common questions about CJC-1295 No DAC and Ipamorelin?
CJC-1295 (No DAC) is a short-acting GHRH analog also called Modified GRF(1-29), and Ipamorelin is a five-amino-acid ghrelin-receptor agonist also called NNC 26-0161 (Raun et al., European Journal of Endocrinology, 1998). The most common questions about CJC-1295 (No DAC) and Ipamorelin cover the difference between 'with DAC' and 'no DAC', what a growth-hormone secretagogue is, and Australian status. Both are laboratory research materials.
CJC-1295 (No DAC) is a synthetic analog of growth-hormone-releasing hormone (GHRH), also called Modified GRF(1-29). It is a short-acting peptide studied in the laboratory for the GHRH signalling pathway. It is a research-use-only reference material, not an approved medicine.
'With DAC' and 'no DAC' are two forms of CJC-1295. The 'with DAC' form carries a Drug Affinity Complex that binds albumin in the blood to make it long-acting, while the 'no DAC' form (Modified GRF(1-29)) is short-acting and clears quickly. This page lists the no-DAC form; the limited human pharmacokinetic data reported by Teichman and colleagues (2006) were for the DAC form.
Ipamorelin is a selective growth-hormone secretagogue - a five-amino-acid peptide that acts as an agonist at the ghrelin receptor (GHS-R1a). It was first described by Raun and colleagues in 1998 and studied in the laboratory for the ghrelin-receptor pathway. Its clinical development was later discontinued, and it is not an approved medicine.
Raun et al. (European Journal of Endocrinology, 1998) reported growth-hormone release in animal experiments with Ipamorelin and measured ACTH and cortisol alongside it. The term secretagogue is the research category in that paper, rather than an established clinical result for this reference material.
Jette et al. (Endocrinology, 2005) examined CJC-1295 with DAC; Raun et al. (European Journal of Endocrinology, 1998) examined Ipamorelin in animals. These papers concern separate compounds and models. The DAC findings do not describe the no-DAC material, and the separate records do not establish a combined clinical outcome.
Raun et al. (European Journal of Endocrinology, 1998) reported growth-hormone release without a significant ACTH or cortisol rise at the studied levels of Ipamorelin in animals. Jette et al. (Endocrinology, 2005) examined the DAC-modified CJC-1295 compound, separate from the no-DAC material. These are separate experimental records, not a combined clinical trial.
No. Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine in Australia - neither is on the Australian Register of Therapeutic Goods, and the TGA has not evaluated either for safety, quality or effectiveness. Ipamorelin's clinical development was discontinued, and CJC-1295 has only limited early human data. Form Labs supplies both strictly as laboratory research materials.
Yes. Growth-hormone-releasing hormone (GHRH) analogs and growth-hormone secretagogues - including CJC-1295 and Ipamorelin - are on the World Anti-Doping Agency (WADA) Prohibited List and are banned in and out of competition. Athletes subject to anti-doping rules should confirm current status directly with WADA. Form Labs supplies both for laboratory research only, not for human use.
The October 2026 Poisons Standard (checked 1 October 2026) lists CJC-1295 (CAS No. 863288-34-0) and ipamorelin in Schedule 4 and in Appendix D, clause 5 - the appendix for poisons whose possession without authority is illegal. The TGA's April 2026 examples of unapproved peptide products name CJC-1295, and Sport Integrity Australia lists CJC-1295 and ipamorelin as prohibited in sport. Form Labs supplies CJC-1295 (No DAC) and Ipamorelin strictly as laboratory research material, not for human or veterinary use.
'For research use only' means CJC-1295 (No DAC) and Ipamorelin are supplied strictly as laboratory reference materials - for in-vitro research, not for use in or on humans or animals. They are not medicines, supplements, or food. Everything on this page describes published research and the identity of this batch, not instructions for use.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
Plain note: CJC-1295 'with DAC' albumin-binding record. Citation: Jette et al., Endocrinology, 2005.. DOI means a permanent article link code; DOI: 10.1210/en.2004-1286.
DOIPlain note: Ipamorelin ghrelin-receptor context record. Citation: Howard et al., Science, 1996.. DOI means a permanent article link code; DOI: 10.1126/science.273.5277.974.
DOIPlain note: Ipamorelin identity and class record. Citation: Raun et al., European Journal of Endocrinology, 1998.. DOI means a permanent article link code; DOI: 10.1530/eje.0.1390552.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
These guides are written and maintained in-house by the Form Laboratories research team. They summarise published literature and link to the cited papers. Form Laboratories did not run those studies. They are not authored by a named clinician and are not medical advice.
Findings remain tied to the study population, model and limits. Cell and animal observations remain separate from clinical results. Everything we supply is research-use-only reference material, not for people or animals.
The product
Form Laboratories - CJC-1295 (No DAC) & Ipamorelin
Ready to see CJC-1295 (No DAC) & Ipamorelin?
- Check available reports and the tests they cover.
- Compare the listed compound, amount and lot with the report.
- Ships from Perth via Australia Post or CouriersPlease in plain packaging.
From
$80.00 AUD
10 mg - 2-8 C
Reference material for laboratory research only.
Related catalogue records
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View CJC-1295 (No DAC) & Ipamorelin - from $80.00 AUD